Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 93,300 shares, a drop of 38.8% from the December 31st total of 152,400 shares. Based on an average trading volume of 111,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday.

Brainstorm Cell Therapeutics Stock Down 2.0 %

Shares of NASDAQ BCLI opened at $1.99 on Wednesday. The business has a fifty day moving average price of $1.92 and a two-hundred day moving average price of $2.97. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.